Does Dr. JOSE NAJUL SEDA have financial conflicts of interest?

Dr. JOSE NAJUL SEDA (M.D.) has received a total of $1,552 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,552 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. JOSE NAJUL SEDA?

According to CMS Open Payments data, Dr. JOSE NAJUL SEDA received funding from CALLIDITAS THERAPEUTICS US ($460), ASTRAZENECA PHARMACEUTICALS ($438), and GENZYME CORPORATION ($118).

Does Dr. JOSE NAJUL SEDA receive research grants or speaking fees?

Dr. JOSE NAJUL SEDA has received $1,552 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. JOSE NAJUL SEDA

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Nephrology

Practice Location: ARECIBO, PR 00612

NPI Number: 1346531704

LIFETIME INDUSTRY VALUE

$1,552

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. NAJUL SEDA is a verified Internal Medicine, Nephrology practitioner based in ARECIBO, PR.

Between 2021 and 2025, Dr. NAJUL SEDA had an overall industry promotional and research financial footprint of $1,552 as recorded in the federal CMS Open Payments database.

$1,552 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. NAJUL SEDA's primary funding source is CALLIDITAS THERAPEUTICS US, which accounts for $460 (representing 29.7% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

CALLIDITAS THERAPEUTICS US

Rank 1

$460

29.7%

ASTRAZENECA PHARMACEUTICALS

Rank 2

$438

28.2%

GENZYME CORPORATION

Rank 3

$118

7.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.